Dishman Carbogen Amcis Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹191.46
Market cap
3,002 Cr
Stock P/E
49.2
P/B
0.45
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 723 Cr | 1,310 Cr | 1,961 Cr | 2,616 Cr | 524 Cr | 1,313 Cr | 682 Cr | 716 Cr | 708 Cr | 653 Cr | 720 Cr | 851 Cr |
| Operating expenses (approx.) | 595 Cr | 1,115 Cr | 1,719 Cr | 2,307 Cr | 499 Cr | 1,137 Cr | 535 Cr | 567 Cr | 545 Cr | 496 Cr | 600 Cr | 673 Cr |
| EBITDA | 128 Cr | 195 Cr | 242 Cr | 309 Cr | 25 Cr | 176 Cr | 148 Cr | 149 Cr | 163 Cr | 157 Cr | 120 Cr | 178 Cr |
| OPM % | 17.7% | 14.9% | 12.3% | 11.8% | 4.8% | 13.4% | 21.7% | 20.8% | 23.0% | 24.1% | 16.6% | 20.9% |
| Other income | 7 Cr | 15 Cr | 21 Cr | 28 Cr | 1 Cr | 8 Cr | 6 Cr | 8 Cr | 25 Cr | 8 Cr | 7 Cr | 16 Cr |
| Interest | 28 Cr | 56 Cr | 89 Cr | 120 Cr | 32 Cr | 69 Cr | 49 Cr | 42 Cr | 43 Cr | 42 Cr | 46 Cr | 43 Cr |
| Depreciation | 70 Cr | 145 Cr | 226 Cr | 311 Cr | 71 Cr | 143 Cr | 72 Cr | 79 Cr | 81 Cr | 84 Cr | 84 Cr | 89 Cr |
| Profit before tax | 29 Cr | -7 Cr | -73 Cr | -122 Cr | -78 Cr | -35 Cr | 27 Cr | 28 Cr | 39 Cr | 31 Cr | -10 Cr | 46 Cr |
| Tax % | 42.4% | -253.0% | -14.3% | -25.5% | -0.0% | -25.5% | 82.9% | -55.6% | 39.5% | -113.7% | -24.2% | 52.9% |
| Net profit | 17 Cr | -24 Cr | -84 Cr | -153 Cr | -78 Cr | -44 Cr | 5 Cr | 43 Cr | 23 Cr | 65 Cr | -13 Cr | 22 Cr |
| EPS (₹) | ₹1.08 | ₹-1.52 | ₹-5.33 | ₹-9.79 | ₹-4.95 | ₹-2.84 | ₹0.30 | ₹2.75 | ₹1.49 | ₹4.16 | ₹-0.83 | ₹1.39 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,059 Cr | 2,044 Cr | 1,912 Cr | 2,141 Cr | 2,413 Cr | 2,616 Cr | 2,712 Cr | 2,932 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,453 Cr | 1,477 Cr | 1,622 Cr | 1,781 Cr | 2,129 Cr | 2,335 Cr | 2,239 Cr | 2,314 Cr | Sign in for TTM |
| EBITDA | 606 Cr | 567 Cr | 291 Cr | 360 Cr | 284 Cr | 280 Cr | 473 Cr | 618 Cr | Sign in for TTM |
| OPM % | 29.4% | 27.7% | 15.2% | 16.8% | 11.8% | 10.7% | 17.4% | 21.1% | Sign in for TTM |
| Other income | 54 Cr | 44 Cr | 38 Cr | 43 Cr | 28 Cr | 28 Cr | 22 Cr | 56 Cr | Sign in for TTM |
| Interest | 57 Cr | 62 Cr | 48 Cr | 57 Cr | 86 Cr | 120 Cr | 159 Cr | 174 Cr | Sign in for TTM |
| Depreciation | 240 Cr | 283 Cr | 308 Cr | 308 Cr | 281 Cr | 311 Cr | 294 Cr | 339 Cr | Sign in for TTM |
| Profit before tax | 309 Cr | 222 Cr | -65 Cr | -4 Cr | -55 Cr | -122 Cr | 19 Cr | 105 Cr | Sign in for TTM |
| Tax % | 31.9% | 18.8% | -153.9% | 523.8% | 45.4% | -25.5% | 83.2% | 7.1% | Sign in for TTM |
| Net profit | 210 Cr | 180 Cr | -165 Cr | 18 Cr | -30 Cr | -153 Cr | 3 Cr | 97 Cr | Sign in for TTM |
| EPS (₹) | ₹13.03 | ₹11.20 | ₹-10.53 | ₹1.15 | ₹-1.90 | ₹-9.79 | ₹0.21 | ₹6.22 | Sign in for TTM |
| Dividend payout % | — | — | — | 0.0% | — | — | 0.0% | 0.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 32 Cr | 31 Cr | 31 Cr | 31 Cr | 31 Cr | 31 Cr | 31 Cr | 31 Cr |
| Reserves | 0.0000 Cr | 0.0000 Cr | 5,667 Cr | 5,518 Cr | 5,778 Cr | 5,596 Cr | 5,800 Cr | 6,64,554 Cr |
| Borrowings | 487 Cr | 479 Cr | 433 Cr | 527 Cr | 1,825 Cr | 1,964 Cr | 935 Cr | 1,241 Cr |
| Other liabilities | 437 Cr | 460 Cr | 403 Cr | 456 Cr | 1,819 Cr | 1,990 Cr | 3,233 Cr | 4,006 Cr |
| Total liabilities | 5,816 Cr | 5,735 Cr | 5,510 Cr | 5,214 Cr | 9,454 Cr | 9,581 Cr | 9,999 Cr | 11,923 Cr |
| Fixed assets (net) | 763 Cr | 755 Cr | 715 Cr | 655 Cr | 1,961 Cr | 2,459 Cr | 2,684 Cr | 2,942 Cr |
| CWIP | 38 Cr | 57 Cr | 79 Cr | 114 Cr | 996 Cr | 501 Cr | 252 Cr | 275 Cr |
| Investments | 2,907 Cr | 2,900 Cr | 2,912 Cr | 3,032 Cr | 249 Cr | 102 Cr | 97 Cr | 91 Cr |
| Other assets | 864 Cr | 962 Cr | 824 Cr | 869 Cr | 1,922 Cr | 1,932 Cr | 2,204 Cr | 2,845 Cr |
| Total assets | 5,816 Cr | 5,735 Cr | 5,510 Cr | 5,214 Cr | 9,454 Cr | 9,581 Cr | 9,999 Cr | 11,923 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 355 Cr | 220 Cr | 384 Cr | 375 Cr | 491 Cr |
| Cash from investing | — | — | — | -619 Cr | -448 Cr | -230 Cr | -192 Cr | -245 Cr |
| Cash from financing | — | — | — | 130 Cr | 250 Cr | -22 Cr | -102 Cr | 201 Cr |
| Net cash flow | — | — | — | -133 Cr | 22 Cr | 132 Cr | 81 Cr | 447 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -109 Cr | -354 Cr | 81 Cr | 158 Cr | 225 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 1131.8% | 905.1% | -0.3% | 0.9% | 0.0% | -0.4% | 2.6% | 3.5% |
| ROE % | 0.0% | 0.0% | -2.9% | 0.3% | -0.5% | -2.7% | 0.1% | 1.5% |
| Debtor days | 86 | 91 | 135 | 79 | 89 | 64 | — | — |
| Inventory days | 411 | 433 | 776 | 685 | 468 | 536 | 553 | 760 |
| Days payable | 173 | 174 | 215 | 187 | 128 | 148 | — | — |
| Cash conversion cycle | 324 | 350 | 696 | 577 | 429 | 452 | 553 | 760 |
| Debt / equity | 0.00 | 0.10 | 0.00 | 0.12 | 0.31 | 0.35 | 0.16 | 0.19 |
| Current ratio | 1.58 | 1.40 | 1.58 | 1.39 | 1.07 | 0.75 | 1.14 | 1.23 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 5.96 | 6.06 | 1.26 | 0.73 |
Compare with peers
Loading peers…